Trials / Completed
CompletedNCT04380714
Changes in the Consumption of Psychoactive Substances During Containment Linked to COVID-19
Changes in the Consumption of Psychoactive Substances by People Incarcerated at the Villeneuve-Lès-Maguelone Prison During Containment Linked to COVID-19.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 700 (actual)
- Sponsor
- University Hospital, Montpellier · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The SARS-CoV 2 pandemic started in China in December 2019, then reached France on January 24, 2020. On March 14, France moved into phase 3 of the epidemic threshold with the implementation of containment measures on March 17 Measures were put in place by N.Belloubet (French Minister of Justice) from March 17, including suspension of visiting rooms and activities in detention. Containment provides boredom and isolation with many potential consequences: sleep disturbance, anxiety, PTSD, depression, suicide, addictive behavior and violence. However,prisoners have a higher prevalence of substance use disorders than the general population. What will have been the impact of the confinement on the consumption of psychoactive substances by prisoners at the Villeneuve Les Maguelone prison. * Anonymous questionnaire from the start * Collection of socio-demographic data * Collection of consumption data before and during containment * Collection of monitoring data
Conditions
Timeline
- Start date
- 2020-05-01
- Primary completion
- 2020-05-30
- Completion
- 2020-08-01
- First posted
- 2020-05-08
- Last updated
- 2020-12-29
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04380714. Inclusion in this directory is not an endorsement.